95 related articles for article (PubMed ID: 12852371)
21. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary sarcoidosis associated with etanercept therapy.
Farah RE; Shay MD
Pharmacotherapy; 2007 Oct; 27(10):1446-8. PubMed ID: 17896899
[TBL] [Abstract][Full Text] [Related]
23. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?
Tiliakos AN; Tiliakos NA
J Rheumatol; 2003 Dec; 30(12):2727. PubMed ID: 14719226
[No Abstract] [Full Text] [Related]
24. Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections.
Sullivan JT; Ni L; Sheelo C; Salfi M; Peloso PM
J Clin Pharmacol; 2006 Jun; 46(6):654-61. PubMed ID: 16707412
[TBL] [Abstract][Full Text] [Related]
25. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug.
Rajakulendran S; Deighton C
Curr Drug Saf; 2006 Aug; 1(3):259-64. PubMed ID: 18690936
[TBL] [Abstract][Full Text] [Related]
26. Is once a week enough?
Bawa S; Hall J; Edmonds S; Webley M
J Rheumatol; 2007 Aug; 34(8):1783; author reply 1783-4. PubMed ID: 17902205
[No Abstract] [Full Text] [Related]
27. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
28. [Etanercept].
Mühlhäuser U; Münzel F; Eschenhagen T
Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1775-8. PubMed ID: 12934172
[No Abstract] [Full Text] [Related]
29. Intraarticular injection of anti-tumor necrosis factor: Comment on the letter by Arnold et al.
Bliddal H
Arthritis Rheum; 2004 Jun; 50(6):2037-8. PubMed ID: 15188385
[No Abstract] [Full Text] [Related]
30. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
Zhou H
J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
[TBL] [Abstract][Full Text] [Related]
31. The medical uses and side effects of etanercept with a focus on cutaneous disease.
Scheinfeld N
J Drugs Dermatol; 2004; 3(6):653-9. PubMed ID: 15624748
[TBL] [Abstract][Full Text] [Related]
32. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
Tsimberidou AM; Giles FJ; Duvic M; Kurzrock R
J Am Acad Dermatol; 2004 Aug; 51(2):200-4. PubMed ID: 15280837
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH
J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
[TBL] [Abstract][Full Text] [Related]
34. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
36. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis.
Etemad L; Yu EB; Wanke LA
Manag Care Interface; 2005 Apr; 18(4):21-7. PubMed ID: 15889759
[TBL] [Abstract][Full Text] [Related]
37. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks.
Boesen M; Boesen L; Jensen KE; Cimmino MA; Torp-Pedersen S; Terslev L; Koenig M; Danneskiold-Samsøe B; Røgind H; Bliddal H
J Rheumatol; 2008 Apr; 35(4):584-91. PubMed ID: 18322991
[TBL] [Abstract][Full Text] [Related]
39. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization.
Bavbek S; Aydın O; Ataman S; Cahill K; Castells M
Allergy; 2011 Sep; 66(9):1256-7. PubMed ID: 21507006
[No Abstract] [Full Text] [Related]
40. Etanercept therapy in children with juvenile rheumatoid arthritis.
Hung JJ; Huang JL
J Microbiol Immunol Infect; 2005 Dec; 38(6):444-6. PubMed ID: 16341346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
